Ris-Rez positive Ph 3 osteosarcoma data in China

Ris-Rez cut progression risk by 67% in Chinese osteosarcoma trial but safety concerns remain.

What the company is saying

GSK plc and Hansoh Pharmaceutical Group Co., Ltd. are highlighting statistically significant phase III data showing Ris-Rez reduced the risk of disease progression or death by 67% versus chemotherapy in relapsed osteosarcoma patients in China. The company frames this as a major advance in a disease with no approved therapies after two prior treatments, emphasizing the unmet need and the lack of standard care. The announcement stresses that this is Hansoh’s second positive phase III study for Ris-Rez in China, positioning the drug as a potential new standard for a rare, high-need population. Hesham Abdullah (GSK SVP, Global Head of Oncology, R&D) and Lu Xie (Peking University, Principal Investigator) are quoted to reinforce the clinical and societal importance of the results. GSK underscores its exclusive rights to Ris-Rez outside China, Hong Kong, Macau, and Taiwan, and its ambition to develop the drug across more than 40 indications by 2040. The company also signals that these results will support a regulatory submission in China and inform global development, but does not claim regulatory approval or commercial launch.

What the data suggests

The ARTEMIS-011 phase III trial met its primary endpoint, with Ris-Rez reducing the risk of disease progression or death by 67% compared to chemotherapy (hazard ratio 0.33, 95% CI 0.20–0.55, p<0.0001) after a median follow-up of 7.1 months. Median progression-free survival was 5.5 months for Ris-Rez versus 1.4 months for chemotherapy, a clinically meaningful improvement in a setting with no approved therapies. Safety data show a high incidence of grade 3 or higher treatment-related adverse events: 93% for Ris-Rez and 83% for chemotherapy, with hematologic events most common. Discontinuation due to adverse events occurred in 4% of Ris-Rez patients and 2% of chemotherapy patients. More than 1,000 patients have received Ris-Rez in GSK’s global EMBOLD clinical trial program. The drug has received orphan drug and breakthrough therapy designations in the US, Japan, and EU for various indications, but no regulatory approvals are reported. The data are robust for efficacy but highlight significant toxicity, and no financial, revenue, or commercialisation figures are disclosed.

Analysis

The announcement presents robust, statistically significant phase III clinical trial results for Ris-Rez in relapsed osteosarcoma, with clear efficacy and safety data. However, the tone extends beyond realised facts by highlighting global development ambitions, regulatory submission plans, and the pursuit of over 40 indications by 2040—none of which are imminent or guaranteed. The majority of measurable progress is limited to the Chinese trial; all commercial and broader clinical benefits are forward-looking and contingent on future regulatory approvals and successful trials. The capital intensity is high, as GSK is advancing a global clinical programme across multiple tumour types, but there is no disclosure of immediate earnings impact or profitability metrics. The narrative is moderately inflated by projecting long-term pipeline potential and regulatory milestones as near-term value, despite the actual realised progress being limited to a single trial result.

Risk flags

• ●Regulatory approval risk is high: while the ARTEMIS-011 trial met its primary endpoint, regulatory submission in China is pending and approval is not guaranteed, especially given the high rate of severe adverse events.
• ●Safety and tolerability concerns are significant: 93% of Ris-Rez patients experienced grade 3 or higher treatment-related adverse events, exceeding the 83% rate in the chemotherapy arm, and discontinuation rates were double for Ris-Rez (4% vs 2%). This may impact regulatory review and real-world uptake.
• ●Commercial and financial outcomes are unproven: no revenue, pricing, or market adoption data are disclosed, and the drug’s global commercial potential remains speculative until approvals are secured outside China.
• ●Pipeline execution risk is material: GSK’s ambition to develop Ris-Rez across more than 40 indications by 2040 is highly capital-intensive and long-dated, with no evidence yet of success beyond the current Chinese trial.
• ●Forward-looking statements dominate the narrative: the announcement projects future regulatory submissions, global trials, and pipeline expansion, but only a single realised clinical milestone is reported, and most value remains contingent on future events.

Bottom line

GSK and Hansoh have delivered robust phase III efficacy data for Ris-Rez in relapsed osteosarcoma in China, with a 67% reduction in risk of progression or death and a median PFS benefit of 4.1 months over chemotherapy. The high rate of severe adverse events (93% for Ris-Rez) raises questions about tolerability and regulatory risk, especially as discontinuation rates are also higher than for chemotherapy. No regulatory approval or commercial launch has occurred, and all financial upside is contingent on future regulatory and market milestones. GSK’s global ambitions for Ris-Rez are long-term and capital-intensive, with more than 1,000 patients dosed but no commercial metrics disclosed. The next concrete step is regulatory submission in China, but investors should recognise that all value beyond this single trial result is speculative and dependent on future approvals and successful expansion into other indications. The most important takeaway is that while the clinical data are strong for efficacy, safety and execution risks remain high, and commercial value is not yet realised.

Announcement summary

(LSE:GSK) GSK plc and Hansoh Pharmaceutical Group Co., Ltd. announced positive results from the ARTEMIS-011 pivotal phase III trial in China evaluating risvutatug rezetecan (Ris-Rez) in patients with relapsed or progressed osteosarcoma after at least two prior lines of systemic therapy. The trial met its primary endpoint, showing Ris-Rez reduced the risk of disease progression or death by 67% compared to chemotherapy, with a hazard ratio of 0.33 (95% CI, 0.20-0.55; p<0.0001) after a median follow-up of 7.1 months. Median progression-free survival (PFS) was 5.5 months for Ris-Rez versus 1.4 months for chemotherapy. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 93% of patients receiving Ris-Rez and 83% of those receiving chemotherapy, with haematologic events being the most common. TRAEs led to discontinuation in 4% of Ris-Rez patients and 2% of chemotherapy patients. The results were presented at the European Society for Medical Oncology (ESMO) Congress 2026 and will support a regulatory submission by Hansoh in China. Hesham Abdullah, Senior Vice President, Global Head of Oncology, R&D, GSK, stated that this is Hansoh’s second positive phase III study for Ris-Rez in China and that the findings are important for patients with relapsed osteosarcoma, where treatment options are extremely limited. Lu Xie, Medical and Pediatric Oncologist for Sarcoma and Principal Investigator of ARTEMIS-011, highlighted the lack of approved therapies and standard of care for relapsed osteosarcoma and the significance of the PFS improvement. GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan, and is advancing a global clinical development programme, including the ongoing phase II EMBOLD Sarcoma-202 trial in advanced osteosarcoma and soft tissue sarcoma. Ris-Rez is a novel investigational antibody-drug conjugate targeting the B7-H3 protein, highly expressed in more than 10 solid tumour types, and is being developed for over 40 indications by 2040. More than 1,000 patients have received Ris-Rez as part of GSK’s global EMBOLD clinical trial programme. Ris-Rez has received orphan drug designations in the US, Japan, and the EU for SCLC, Breakthrough Therapy Designation in the US, and Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC, as well as Breakthrough Therapy Designation in the US for relapsed or refractory osteosarcoma. ARTEMIS-011 was a multicentre, randomised, open-label phase III trial in China, randomising patients 1:1 to receive Ris-Rez 12.0 mg/kg every 3 weeks or gemcitabine 1,000 mg/m² on days 1 and 8 plus docetaxel 75 mg/m² on day 8 every 3 weeks. The primary endpoint was IRC-assessed PFS, with secondary endpoints including investigator-assessed overall survival, investigator-assessed PFS, safety, IRC-assessed objective response rate, disease control rate, and duration of response. The EMBOLD Sarcoma-202 phase Ib/II study is evaluating Ris-Rez in previously treated unresectable advanced or metastatic sarcomas globally, with primary endpoints of PFS and confirmed ORR, and secondary endpoints including safety, DOR, and patient-reported outcomes. Osteosarcoma is a rare cancer with a global incidence of approximately 3.4 cases per million people per year, mainly affecting children and young adults, and accounts for 20-40% of all bone cancers. Following first-line chemotherapy, treatment options for relapsed osteosarcoma are severely limited, with no clear standard of care or approved therapies after two prior lines of treatment.

Disagree with this article?